Modeling energy intake and body weight effects of a long-acting amylin analogue
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology
Link
http://link.springer.com/article/10.1007/s10928-017-9557-6/fulltext.html
Reference57 articles.
1. Fernstrom JD, Choi S (2008) The development of tolerance to drugs that suppress food intake. Pharmacol Ther 117(1):105–122. https://doi.org/10.1016/j.pharmthera.2007.09.001
2. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295(7):761–775. https://doi.org/10.1001/jama.295.7.761
3. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K (1996) A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 4(3):263–270
4. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, Van Gaal LF (2000) Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine trial of obesity reduction and maintenance. Lancet 356(9248):2119–2125
5. Wirth A, Krause J (2001) Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 286(11):1331–1339
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The long-acting amylin/calcitonin receptor agonist ZP5461 suppresses food intake and body weight in male rats;American Journal of Physiology-Regulatory, Integrative and Comparative Physiology;2021-08-01
2. Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat;Frontiers in Endocrinology;2021-01-08
3. Systemic and Central Amylin, Amylin Receptor Signaling, and Their Physiological and Pathophysiological Roles in Metabolism;Comprehensive Physiology;2020-07-08
4. BZ043, a novel long-acting amylin analog, reduces gastric emptying, food intake, glycemia and insulin requirement in streptozotocin-induced diabetic rats;Peptides;2019-04
5. New advances and novel approaches in obesity pharmacotherapy;Current Opinion in Endocrine and Metabolic Research;2019-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3